{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:15:00Z","timestamp":1764767700451,"version":"3.46.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Fibromyalgie ist ein chronisches Schmerzsyndrom mit erheblicher k\u00f6rperlicher und psychischer Belastung. Die Wirksamkeit medikament\u00f6ser Therapien ist begrenzt, w\u00e4hrend nichtmedikament\u00f6se Selbstmanagementstrategien wie Bewegung, kognitive Verhaltenstherapie (KVT) und achtsamkeitsbasierte Verfahren effizient sind und empfohlen werden, aber nur begrenzt zum Einsatz kommen. Diese lassen sich zunehmend auch online durchf\u00fchren, was den Zugang erleichtert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Ziel dieses Beitrags ist es, auf Basis des aktuellen Stands zu pr\u00fcfen, wie Selbstmanagementans\u00e4tze bei der Fibromyalgie digital \u00fcber Apps umgesetzt werden und wie digitale Therapien z.\u202fB. mittels Wearables, KI(k\u00fcnstliche Intelligenz)-Modellen und Chatbots weiterentwickelt werden k\u00f6nnen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>Bestehende digitale Anwendungen f\u00fcr Fibromyalgie und neue Konzepte wurden bewertet. Exemplarisch wurde eine eigene entwickelte App POCOS (Patient Organiser and Companion System) mit und ohne KI-Chatbot in Fokusgruppen mit Patient:innen diskutiert.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Zunehmend erh\u00e4ltliche digitale Anwendungen f\u00fcr Fibromyalgie decken bislang prim\u00e4r psychoedukative Inhalte ab, w\u00e4hrend Bewegungsprogramme und multimodale Konzepte seltener integriert sind, aber evidenzbasiert sind und von Patient:innen gew\u00fcnscht werden. Klinische Studien konnten einen positiven Effekt einzelner Online-Programme nachweisen. Fokusgruppen pl\u00e4dieren f\u00fcr eine personalisierte, niedrigschwellige und benutzerfreundliche Gestaltung der Apps. Der Einsatz von KI-gest\u00fctzten Chatbots in diesem Kontext ist m\u00f6glich und sinnvoll, bedarf jedoch strukturierter Inhalte und regulatorischer Rahmenbedingungen. Auf diagnostischer Ebene k\u00f6nnen durch maschinelles Lernen \u201eFibromyalgietypen\u201c identifiziert werden, die hilfreich f\u00fcr eine personalisierte Behandlung sind.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die digitale Behandlung der Fibromyalgie ist m\u00f6glich und wirksam, erfordert aber eine konsequente evidenzbasierte Umsetzung, Partizipation von Betroffenen, technische Interoperabilit\u00e4t und eine sensible Gestaltung f\u00fcr die heterogene Zielgruppe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-025-01738-5","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T15:48:29Z","timestamp":1761320909000},"page":"786-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digitale Behandlung der Fibromyalgie","Digital treatment of fibromyalgia"],"prefix":"10.1007","volume":"84","author":[{"given":"Thomas","family":"H\u00fcgle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"issue":"9","key":"1738_CR1","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00296-017-3725-2","volume":"37","author":"F Heidari","year":"2017","unstructured":"Heidari\u00a0F, Afshari\u00a0M, Moosazadeh\u00a0M (2017) Prevalence of fibromyalgia in general population and patients, a\u00a0systematic review and meta-analysis. rheumatol Int 37(9):1527\u20131539. https:\/\/doi.org\/10.1007\/s00296-017-3725-2","journal-title":"rheumatol Int"},{"issue":"6","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.55563\/clinexprheumatol\/z1jcry","volume":"43","author":"A Di Bari","year":"2025","unstructured":"Di Bari\u00a0A, Demo\u00a0G, Patron\u00a0E (2025) Unravelling the relationship between anxiety, autonomic nervous system dysfunction and fibromyalgia: a\u00a0systematic review. Clin Exp Rheumatol 43(6):1136\u20131145. https:\/\/doi.org\/10.55563\/clinexprheumatol\/z1jcry","journal-title":"Clin Exp Rheumatol"},{"key":"1738_CR3","doi-asserted-by":"publisher","first-page":"152060","DOI":"10.1016\/j.semarthrit.2022.152060","volume":"56","author":"M D\u2019Onghia","year":"2022","unstructured":"D\u2019Onghia\u00a0M, Ciaffi\u00a0J, Ruscitti\u00a0P et\u00a0al (2022) The economic burden of fibromyalgia: A\u00a0systematic literature review. Semin Arthritis Rheum 56:152060. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152060","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1738_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12888-025-06708-4","volume":"25","author":"A Rahangdale","year":"2025","unstructured":"Rahangdale\u00a0A, Ferraro\u00a0J (2025) Assessing comorbid PTSD, depression, and anxiety in fibromyalgia patients: a\u00a0retrospective observational study. Bmc Psychiatry 25(1):444\u2013441. https:\/\/doi.org\/10.1186\/s12888-025-06708-4","journal-title":"Bmc Psychiatry"},{"issue":"2","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"rkaf024","DOI":"10.1093\/rap\/rkaf024","volume":"9","author":"T Pretat","year":"2025","unstructured":"Pretat\u00a0T, H\u00fcgle\u00a0T, Mettler\u00a0J, Suter\u00a0M, Jean-Scherb\u00a0S, Ming-Azevedo\u00a0P (2025) Clinical predictors of immediate response to a\u00a0multimodal inpatient programme for chronic refractory musculoskeletal pain syndromes\u2014a cross-sectional study. Rheumatol Adv Pract 9(2):rkaf24. https:\/\/doi.org\/10.1093\/rap\/rkaf024","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"1738_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1002\/art.27497","volume":"62","author":"V Napadow","year":"2010","unstructured":"Napadow\u00a0V, LaCount\u00a0L, Park\u00a0K, As-Sanie\u00a0S, Clauw\u00a0DJ, Harris\u00a0RE (2010) Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum 62(8):2545\u20132555. https:\/\/doi.org\/10.1002\/art.27497","journal-title":"Arthritis Rheum"},{"key":"1738_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124166","author":"E Abenavoli","year":"2025","unstructured":"Abenavoli\u00a0E, Berti\u00a0V, Nerattini\u00a0M et\u00a0al (2025) Fibromyalgia in the Era of Brain PET\/CT Imaging. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm14124166 (Jun 12)","journal-title":"J Clin Med"},{"key":"1738_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071543","author":"LN Jurado-Priego","year":"2024","unstructured":"Jurado-Priego\u00a0LN, Cueto-Ure\u00f1a\u00a0C, Ram\u00edrez-Exp\u00f3sito\u00a0MJ, Fibromyalgia\u00a0M\u2011MJM (2024) A\u00a0Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12071543 (Jul 11)","journal-title":"Biomedicines"},{"key":"1738_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02204-x","author":"H Clarke","year":"2025","unstructured":"Clarke\u00a0H, Peer\u00a0M, Miles\u00a0S, Fitzcharles\u00a0MA (2025) Managing Pain in Fibromyalgia: Current and Future. Options drugs. https:\/\/doi.org\/10.1007\/s40265-025-02204-x (Jul 18)","journal-title":"Options drugs"},{"key":"1738_CR10","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1136\/annrheumdis-2017-211587","volume":"12","author":"GJ Macfarlane","year":"2017","unstructured":"Macfarlane\u00a0GJ, Kronisch\u00a0C, Atzeni\u00a0F et\u00a0al (2017) EULAR recommendations for management of fibromyalgia. Ann Rheum Dis 12:e54","journal-title":"Ann Rheum Dis"},{"key":"1738_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/10538127251337393","author":"F Araya-Quintanilla","year":"2025","unstructured":"Araya-Quintanilla\u00a0F, Cuyul-V\u00e1squez\u00a0I, Lizama-Lefno\u00a0A et\u00a0al (2025) Effectiveness of multicomponent treatment compared with other therapeutic interventions in patients with fibromyalgia: A\u00a0systematic review with meta-analysis. J\u00a0Back Musculoskelet Rehabil. https:\/\/doi.org\/10.1177\/10538127251337393 (May 21)","journal-title":"J Back Musculoskelet Rehabil"},{"issue":"10","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00296-020-04621-5","volume":"40","author":"GT Jones","year":"2020","unstructured":"Jones\u00a0GT, Mallawaarachchi\u00a0B, Shim\u00a0J, Lock\u00a0J, Macfarlane\u00a0GJ (2020) The prevalence of fibromyalgia in axial spondyloarthritis. rheumatol Int 40(10):1581\u20131591. https:\/\/doi.org\/10.1007\/s00296-020-04621-5","journal-title":"rheumatol Int"},{"issue":"2","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1573397118666220902100151","volume":"19","author":"S Olfa","year":"2023","unstructured":"Olfa\u00a0S, Bouden\u00a0S, Sahli\u00a0M et\u00a0al (2023) Fibromyalgia in Spondyloarthritis: Prevalence and Effect on Disease Activity and Treatment. Curr Rheumatol Rev 19(2):214\u2013221. https:\/\/doi.org\/10.2174\/1573397118666220902100151","journal-title":"Curr Rheumatol Rev"},{"issue":"2","key":"1738_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pain.2010.03.034","volume":"150","author":"S Perrot","year":"2010","unstructured":"Perrot\u00a0S, Bouhassira\u00a0D, Fermanian\u00a0J (2010) Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 150(2):250\u2013256. https:\/\/doi.org\/10.1016\/j.pain.2010.03.034","journal-title":"Pain."},{"issue":"1","key":"1738_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s42358-025-00457-4","volume":"65","author":"J Mettler","year":"2025","unstructured":"Mettler\u00a0J, Ming-Azevedo\u00a0P, H\u00fcgle\u00a0T (2025) Fibromyalgia with concomitant immune-mediated rheumatic diseases: an evaluation of clinical characteristics, diagnostic criteria and multimodal treatment outcomes. Adv Rheumatol 65(1):27\u201312. https:\/\/doi.org\/10.1186\/s42358-025-00457-4","journal-title":"Adv Rheumatol"},{"issue":"6","key":"1738_CR16","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.55563\/clinexprheumatol\/i7kod6","volume":"41","author":"B Mosch","year":"2023","unstructured":"Mosch\u00a0B, Hagena\u00a0V, Herpertz\u00a0S, Diers\u00a0M (2023) Adverse effects of the COVID-19 pandemic on fibromyalgia patients in Germany: a\u00a0longitudinal investigation including pre-pandemic data of pain and health-related outcomes. Clin Exp Rheumatol 41(6):1301\u20131309. https:\/\/doi.org\/10.55563\/clinexprheumatol\/i7kod6","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1007\/s00296-024-05616-2","volume":"44","author":"AC Gianloren\u00e7o","year":"2024","unstructured":"Gianloren\u00e7o\u00a0AC, Costa\u00a0V, Fabris-Moraes\u00a0W et\u00a0al (2024) Cluster analysis in fibromyalgia: a\u00a0systematic review. rheumatol Int 44(11):2389\u20132402. https:\/\/doi.org\/10.1007\/s00296-024-05616-2","journal-title":"rheumatol Int"},{"key":"1738_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11699","author":"T H\u00fcgle","year":"2024","unstructured":"H\u00fcgle\u00a0T, Pr\u00e9tat\u00a0T, Suter\u00a0M, Lovejoy\u00a0C, Azevedo\u00a0MP (2024) Disease Phenotypes in Refractory Musculoskeletal Pain Syndromes Identified by Unsupervised Machine Learning. Acr Open Rheumatol. https:\/\/doi.org\/10.1002\/acr2.11699 (Aug 29)","journal-title":"Acr Open Rheumatol"},{"issue":"10","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","volume":"80","author":"E Nikiphorou","year":"2021","unstructured":"Nikiphorou\u00a0E, Santos\u00a0EJF, Marques\u00a0A et\u00a0al (2021) EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis 80(10):1278\u20131285. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220249 (10 2021)","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejp.1121","volume":"22","author":"K Bernardy","year":"2018","unstructured":"Bernardy\u00a0K, Klose\u00a0P, Welsch\u00a0P, H\u00e4user\u00a0W (2018) Efficacy, acceptability and safety of cognitive behavioural therapies in fibromyalgia syndrome\u2014A systematic review and meta-analysis of randomized controlled trials. Eur J Pain 22(2):242\u2013260. https:\/\/doi.org\/10.1002\/ejp.1121","journal-title":"Eur J Pain"},{"key":"1738_CR21","doi-asserted-by":"publisher","first-page":"1160908","DOI":"10.3389\/fpsyt.2023.1160908","volume":"14","author":"F Maas Genannt Bermpohl","year":"2023","unstructured":"Maas Genannt Bermpohl\u00a0F, H\u00fclsmann\u00a0L, Martin\u00a0A (2023) Efficacy of mindfulness- and acceptance-based cognitive-behavioral therapies for bodily distress in adults: a\u00a0meta-analysis. Front Psychiatry 14:1160908. https:\/\/doi.org\/10.3389\/fpsyt.2023.1160908","journal-title":"Front Psychiatry"},{"issue":"5","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/09593985.2016.1194646","volume":"32","author":"A Louw","year":"2016","unstructured":"Louw\u00a0A, Zimney\u00a0K, Puentedura\u00a0EJ, Diener\u00a0I (2016) The efficacy of pain neuroscience education on musculoskeletal pain: A\u00a0systematic review of the literature. Physiother Theory Pract 32(5):332\u2013355. https:\/\/doi.org\/10.1080\/09593985.2016.1194646","journal-title":"Physiother Theory Pract"},{"issue":"5","key":"1738_CR23","doi-asserted-by":"publisher","first-page":"e35371","DOI":"10.2196\/35371","volume":"24","author":"R Jakob","year":"2022","unstructured":"Jakob\u00a0R, Harperink\u00a0S, Rudolf\u00a0AM et\u00a0al (2022) Factors Influencing Adherence to mHealth Apps for Prevention or Management of Noncommunicable Diseases: Systematic Review. J\u00a0Med Internet Res 24(5):e35371\u201325. https:\/\/doi.org\/10.2196\/35371","journal-title":"J Med Internet Res"},{"issue":"10","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00393-024-01570-3","volume":"83","author":"J Knitza","year":"2024","unstructured":"Knitza\u00a0J, Krusche\u00a0M, Chehab\u00a0G, Specker\u00a0C, Richter\u00a0JG (2024) Digital health applications-What we should know as rheumatologists. Z\u00a0Rheumatol 83(10):859\u2013865. https:\/\/doi.org\/10.1007\/s00393-024-01570-3 (Digitale Gesundheitsanwendungen \u2013 was sollten wir als Rheumatolog:innen wissen)","journal-title":"Z Rheumatol"},{"issue":"2","key":"1738_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40744-025-00744-y","volume":"12","author":"A Albrecht","year":"2025","unstructured":"Albrecht\u00a0A, Taubmann\u00a0J, Minopoulou\u00a0I et\u00a0al (2025) Real-World-Evidence of Digital Health Applications (DiGAs) in Rheumatology: Insights from the DiGAReal Registry. Rheumatol Ther 12(2):267\u2013282. https:\/\/doi.org\/10.1007\/s40744-025-00744-y","journal-title":"Rheumatol Ther"},{"issue":"8","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1111\/ner.13463","volume":"25","author":"RN Jamison","year":"2022","unstructured":"Jamison\u00a0RN, Curran\u00a0S, Wan\u00a0L, Ross\u00a0EL, Gilligan\u00a0CJ, Edwards\u00a0RR (2022) Higher Pain Sensitivity Predicts Efficacy of a\u00a0Wearable Transcutaneous Electrical Nerve Stimulation Device for Persons With Fibromyalgia: A\u00a0Randomized Double-Blind Sham-Controlled Trial. Neuromodulation 25(8):1410\u20131420. https:\/\/doi.org\/10.1111\/ner.13463","journal-title":"Neuromodulation"},{"key":"1738_CR27","doi-asserted-by":"publisher","unstructured":"Gendreau RM, McCracken LM, Williams DA, et al. (2024) Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3 multicentre randomised controlled trial The Lancet 404(10450):364-374. https:\/\/doi.org\/10.1016\/S0140-6736(24)00909-7","DOI":"10.1016\/S0140-6736(24)00909-7"},{"key":"1738_CR28","unstructured":"Therapeutics S https:\/\/swingtherapeutics.com\/stanza-shows-lasting-benefits-for-fibromyalgia-symptoms\/?utm_source=chatgpt.com"},{"key":"1738_CR29","doi-asserted-by":"publisher","first-page":"e51974","DOI":"10.2196\/51974","volume":"13","author":"R Monachelli","year":"2024","unstructured":"Monachelli\u00a0R, Davis\u00a0SW, Barnard\u00a0A, Longmire\u00a0M, Docherty\u00a0JP, Oakley-Girvan\u00a0I (2024) Designing mHealth Apps to Incorporate Evidence-Based Techniques for Prolonging User Engagement. Interact J Med Res 13:e51974. https:\/\/doi.org\/10.2196\/51974 (Mar 26)","journal-title":"Interact J Med Res"},{"issue":"1","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12911-024-02738-2","volume":"24","author":"Z Galavi","year":"2024","unstructured":"Galavi\u00a0Z, Montazeri\u00a0M, Khajouei\u00a0R (2024) Which criteria are important in usability evaluation of mHealth applications: an umbrella review. BMC Med Inform Decis Mak 24(1):365. https:\/\/doi.org\/10.1186\/s12911-024-02738-2 (Nov 29)","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"1738_CR31","doi-asserted-by":"publisher","first-page":"e32193","DOI":"10.2196\/32193","volume":"11","author":"M Blanchard","year":"2022","unstructured":"Blanchard\u00a0M, Backhaus\u00a0L, Azevedo\u00a0MP, H\u00fcgle\u00a0T (2022) An mHealth App for Fibromyalgia-like Post-COVID-19 Syndrome: Protocol for the Analysis of User Experience and Clinical Data. JMIR Res Protoc 11(2):e32193. https:\/\/doi.org\/10.2196\/32193 (Feb 4)","journal-title":"JMIR Res Protoc"},{"key":"1738_CR32","doi-asserted-by":"publisher","first-page":"e50832","DOI":"10.2196\/50832","volume":"8","author":"M Blanchard","year":"2024","unstructured":"Blanchard\u00a0M, Koller\u00a0CN, Azevedo\u00a0PM, Pr\u00e9tat\u00a0T, H\u00fcgle\u00a0T (2024) Development of a\u00a0Management App for Postviral Fibromyalgia-Like Symptoms: Patient Preference-Guided Approach. Jmir Form Res 8:e50832. https:\/\/doi.org\/10.2196\/50832 (Apr 19)","journal-title":"Jmir Form Res"},{"key":"1738_CR33","unstructured":"Sensor RGL Learning the Language of Wearable Sensors. https:\/\/research.google\/blog\/sensorlm-learning-the-language-of-wearable-sensors\/"},{"key":"1738_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000001087","author":"S La Bella","year":"2025","unstructured":"La Bella\u00a0S, Gupta\u00a0L, Venerito\u00a0V (2025) AI am the future: artificial intelligence in pediatric rheumatology. Curr Opin Rheumatol. https:\/\/doi.org\/10.1097\/bor.0000000000001087 (Mar 12)","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1738_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard-2024-226202","volume":"84","author":"SPS Scaff","year":"2025","unstructured":"Scaff\u00a0SPS, Reis\u00a0FJJ, Ferreira\u00a0GE, Jacob\u00a0MF, Saragiotto\u00a0BT (2025) Assessing the performance of AI chatbots in answering patients\u2019 common questions about low back pain. Ann Rheum Dis 84(1):143\u2013149. https:\/\/doi.org\/10.1136\/ard-2024-226202","journal-title":"Ann Rheum Dis"},{"key":"1738_CR36","doi-asserted-by":"publisher","first-page":"e47267","DOI":"10.2196\/47267","volume":"7","author":"NE Andrews","year":"2023","unstructured":"Andrews\u00a0NE, Ireland\u00a0D, Vijayakumar\u00a0P et\u00a0al (2023) Acceptability of a\u00a0Pain History Assessment and Education Chatbot (Dolores) Across Age Groups in Populations With Chronic Pain: Development and Pilot Testing. Jmir Form Res 7:e47267. https:\/\/doi.org\/10.2196\/47267 (Oct 6)","journal-title":"Jmir Form Res"},{"key":"1738_CR37","doi-asserted-by":"publisher","first-page":"152262","DOI":"10.1016\/j.semarthrit.2023.152262","volume":"63","author":"JJ Rasker","year":"2023","unstructured":"Rasker\u00a0JJ, Wolfe\u00a0F, Michaud\u00a0K, Ten Klooster\u00a0PM (2023) Looking at Fibromyalgia differently\u2014the meaning and consequences of fibromyalgia as a\u00a0dimensional disorder. Semin Arthritis Rheum 63:152262. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152262","journal-title":"Semin Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01738-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:51:47Z","timestamp":1764766307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01738-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01738-5","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0H\u00fcgle gibt an, dass kein Interessenkonflikt besteht. Finanzielle Entsch\u00e4digung f\u00fcr Vortr\u00e4ge oder Konferenzen von verschiedenen Firmen u.\u202fa. AbbVie, Johnson & Johnson, BMS, GSK, Novartis und Pfizer. Lizenzrechte und Anteile an Atreon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}